Skip to main content

News and Announcements

Browse the articles below to learn more about our faculty’s latest achievements, awards and honors.

  • 03.21.2024

    Edward M. Schaeffer, MD, PhD, explores the latest developments and future prospects of PSMA-PET technology in the realm of prostate cancer diagnosis and treatment. With his vast knowledge and scholarly contributions to the field, Dr. Schaeffer provides invaluable insights into the evolving role of PSMA-PET imaging, highlighting its potential to revolutionize the way prostate cancer is detected, staged, and managed. 

  • 03.18.2024

    Two methods of prostate cancer biopsy demonstrated similar, minimal rates of infection in patients with prostate cancer, according to a recent Northwestern Medicine study published in the journal European Urology.

  • 03.07.2024

    Amy Krambeck, MD, delves into the complexities of kidney stone formation and recurrence, emphasizing the pivotal role dietary changes play in mitigating risks. Amidst the plethora of advice on what to avoid, she highlights key dietary habits that can proactively prevent the onset of kidney stones.

  • 03.04.2024

    Adam B. Murphy, MD, MBA, MSCI, delves into the pivotal findings and essential insights gleaned from the study titled "Development and validation of a prostate biopsy risk calculator in Black Men," where he assumed the role of senior author. Dr. Murphy sheds light on the significance of the research outcomes and their implications, offering valuable perspectives on the development and validation process of a prostate biopsy risk calculator tailored specifically for Black men.

  • 02.27.2024

    Peter N. Tsambarlis, MD, discusses regenerative therapies for erectile dysfunction, providing an overview and addressing common patient inquiries about these treatments for ED.

  • 02.23.2024

    Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer — its hunger for cholesterol — and how to sneakily use that to destroy it.

  • 02.15.2024

    Increased expression of specific genes in prostate cancer patients may predict whether or not the cancer will respond well to hormone therapy, according to a new study published in Nature Communications.

  • 02.06.2024

    Robert Brannigan, MD, Kristin Smith, and Joshua A. Halpern, MD, MS, engage in a comprehensive discussion regarding the innovative oncofertility program at Northwestern University. As pioneers in the field, Dr. Brannigan and his esteemed colleagues shed light on the multidisciplinary approach adopted by the program, which aims to address the unique reproductive concerns of cancer patients. Through their expertise in urology, oncology, and reproductive endocrinology, they explore the latest advancements and personalized strategies for preserving fertility in individuals undergoing cancer treatment. 

  • 02.02.2024

    During a discussion with CancerNetwork® at the 2024 Genitourinary Cancers Symposium, Joshua Meeks, MD, PhD, Associate Professor of Urology, Biochemistry, and Molecular Genetics, as well as the Section Chief of Robotic Surgery at the Jesse Brown VA Medical Center, shared insights from his presentation on the current BCG shortage. He highlighted potential strategies for oncologists facing this scarcity, such as considering gemcitabine/docetaxel or cystectomy as alternative approaches to manage the disease when BCG supplies are limited.

  • 02.01.2024

    Adam Murphy, MD, MBA, MSCI, discusses the heightened risk of prostate cancer among Black men. Dr. Murphy delves into the various factors contributing to this increased vulnerability, such as genetic predispositions, socioeconomic disparities, and healthcare access issues. Dr. Murphy emphasizes the importance of addressing these factors to reduce the disproportionate impact of prostate cancer on Black men and advocates for tailored strategies in screening, prevention, and treatment.

  • 01.29.2024

    Hiten Patel. MD, MPH, discusses into his team's study, exploring the utilization of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Motivated by observed low utilization rates in practice, the research aims to unravel the elective and eligibility factors influencing the application of this treatment.

  • 01.25.2024

    In the wake of public figures like Lloyd Austin and Ryne Sandberg confronting the challenges of prostate cancer, Shailajit Kundu, MD, takes part in an insightful conversation with NBC Chicago's Lauren Petty to provides a comprehensive exploration of the complexities surrounding prostate cancer. Dr. Kundu discusses the advancements in treatment of prostate cancer, the importance of early detection, and the impact on both patients and their communities. 

  • 01.22.2024

    In a recent interview with Urology Times, Vikas Desai, MD delves into the forefront of advancements in treatments for incontinence and Overactive Bladder (OAB). Dr. Desai provides insightful commentary on the latest breakthroughs, showcasing the ongoing progress in urological care. From innovative therapies to emerging technologies, the discussion offers a comprehensive overview of the dynamic landscape in addressing incontinence and OAB.

  • 01.05.2024

    In the discussion about the management of low-risk prostate cancer through active surveillance, Dr. Catalona undergoes a notable shift in perspective.  Initially opposed to active surveillance, he has since adjusted his views, preferring a more conservative approach. This discussion centers on this shift in mindset and its impact on the approach to active surveillance in low-risk prostate cancer cases.

  • 12.25.2023

    As the year wraps up, Urology Times rolls out their top 10 urologic imaging stories of 2023. View highlights as they revisit articles exploring cutting-edge imaging agents in Urology, with standout contributions from the brilliant minds at Northwestern Urology.

  • 12.20.2023
    A team of Northwestern Medicine investigators, including Dr. Joshua Meeks, MD, PhD, has identified localized molecular mechanisms associated with a genetic mutation prevalent in various cancers. This discovery holds potential as a biomarker for enhanced patient stratification and treatment. The study points towards promising prospects for developing personalized cancer treatments tailored to the specific genetic alterations found at the tumor site.
  • 11.29.2023
    In a conversation with CancerNetwork® during the 2023 Society of Urologic Oncology (SUO) Annual Meeting, William J. Catalona, MD, underscores the crucial need for genetic studies in prostate cancer. Dr. Catalona emphasizes the importance of advancing understanding and developing robust guidelines in this area. He points out that genetic testing for localized diagnosis in prostate cancer is still in its early stages across various cancer types, emphasizing the necessity for additional research to accumulate firm evidence and drive progress in the field.
  • 11.26.2023
    Adam B. Murphy, MD, MBA, MSCI, discusses a significant secondary discovery related to the impact of perceived patient health literacy on urologists' treatment decisions for prostate cancer. This insight is derived from the study titled "Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial," where Dr. Murphy served as the senior author.
  • 11.10.2023
    Illinois state representative Lashawn Ford and Dr. Adam Murphy discuss the important of early detestion of prostate cancer and how facial hair is now being used to raise awareness for men's health specifically prostate cancer, testicular cancer and mental health. Movember is an annual initiative when men are encouraged to grow moustaches during the month of November.
  • 11.07.2023
    Adam B. Murphy, MD, MBA, MSCI, provides insights into the study titled "Impact of genomic testing on urologists' treatment preferences in favorable-risk prostate cancer: A randomized trial," in which he served as the senior author. He discusses the study's background and significant findings.
  • 10.23.2023

    Scientists have linked mutations in 11 genes with aggressive prostate cancer, according to the largest-ever study of its kind recently published in JAMA Oncology.

  • 10.16.2023
    Hormone replacement therapy (HRT) extends beyond women, as men also undergo changes in hormone levels, particularly a gradual decline in testosterone after age 30. While men don't experience a menopausal shift, factors like chronic conditions, including obesity and type 2 diabetes, can contribute to reduced testosterone levels. Robert Brannigan, MD explains the diagnosis of low testosterone, outlines symptoms and risk factors, and delves into available hormone therapy options for men, shedding light on potential risks associated with such treatments.
  • 10.04.2023
    Edward Schaeffer, MD, PhD provides insights on strategies to address nocturia, the condition of waking up during the night to urinate. Dr. Schaeffer suggests lifestyle changes such as limiting caffeine and alcohol intake, managing fluid consumption before bedtime, and addressing underlying health conditions.
  • 09.12.2023
    Edward M. Schaeffer, MD, PhD, shares his journey of becoming involved with the book "Dr. Patrick Walsh's Guide to Surviving Prostate Cancer."
  • 09.05.2023

    In the quest to predict prostate cancer risk, polygenic risk scores (PRS) have taken center stage. William Catalona, MD provides his insight, which consider multiple genetic factors, are increasingly being studied as potential tools for assessing an individual's risk of developing prostate cancer.

  • 07.06.2023
    Edward M. Schaeffer, MD, PhD, discusses the emergence of prostate-specific membrane antigen-targeting agents in prostate cancer. Dr. Schaeffer also highlights that these agents can help improve the accuracy of imaging tests and provide valuable information for treatment decisions.
  • 07.05.2023
    Hiten Patel, MD, MPH, sheds light on the groundbreaking initiatives and advancements in prostate cancer care within the Veterans Health Administration (VA) system. Dr. Patel emphasizes the significance of addressing the specific needs of veterans in prostate cancer diagnosis, treatment, and survivorship. 
  • 07.04.2023
    Conor Driscoll, MD, a PGY3 Urology resident, discusses the research conducted on the impact of TNF-alpha inhibitor use and prostate cancer risk. The study found no significant association, indicating that these medications are unlikely to increase prostate cancer risk.
  • 07.03.2023
    Edward Schaeffer, MD, PhD, discusses current urologic research at Northwestern University, emphasizing the importance of precision medicine and advancements in genomic testing for prostate cancer. He also emphasizes the collaborative efforts between different disciplines within the university to enhance patient care and outcomes.

Follow Urology on